Cargando…

An overview of potential inhibitors targeting non-structural proteins 3 (PL(pro) and Mac1) and 5 (3CL(pro)/M(pro)) of SARS-CoV-2

There is an urgent need to develop effective treatments for coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rapid spread of SARS-CoV-2 has resulted in a global pandemic that has not only affected the daily lives of individuals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Fangfang, Gao, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Research Network of Computational and Structural Biotechnology 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382591/ https://www.ncbi.nlm.nih.gov/pubmed/34457214 http://dx.doi.org/10.1016/j.csbj.2021.08.036

Ejemplares similares

Discovery of PL(pro) and M(pro) Inhibitors for SARS-CoV-2
por: Puhl, Ana C., et al.
Publicado: (2023)

Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021)

Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PL(pro) and M(pro)/ 3CL(pro): molecular docking and simulation studies of three pertinent medicinal plant natural components
por: Verma, Devvret, et al.
Publicado: (2021)

Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 M(Pro) and PL(Pro)
por: Kattula, Bhavita, et al.
Publicado: (2023)

Dual targeting of 3CL(pro) and PL(pro) of SARS-CoV-2: A novel structure-based design approach to treat COVID-19
por: Rajpoot, Sajjan, et al.
Publicado: (2020)

Effects of diarylbutane lignans from Schisandra chinensis fruit on SARS-CoV-2 3CL(pro) and PL(pro) and their in vitro anti-inflammatory properties
por: Li, Bin, et al.
Publicado: (2023)

“Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL(pro) and PL(pro)"
por: Bhowmik, Deep, et al.
Publicado: (2021)

Schaftoside inhibits 3CL(pro) and PL(pro) of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19
por: Yi, Yang, et al.
Publicado: (2022)

Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M(pro)/3CL(pro) in Living Cells
por: Moghadasi, Seyed Arad, et al.
Publicado: (2022)

Profiling of Substrate Specificity of SARS-CoV 3CL(pro)
por: Chuck, Chi-Pang, et al.
Publicado: (2010)

FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 M(pro) and PL(pro)
por: Tan, Haozhou, et al.
Publicado: (2023)

In silico analysis of echinocandins binding to the main proteases of coronaviruses PEDV (3CL(pro)) and SARS-CoV-2 (M(pro))
por: Vergoten, Gérard, et al.
Publicado: (2021)

Prioritisation of Compounds for 3CL(pro) Inhibitor Development on SARS-CoV-2 Variants
por: Jukič, Marko, et al.
Publicado: (2021)

Spatial and temporal roles of SARS‐CoV PL(pro)—A snapshot
por: Yan, Shaomin, et al.
Publicado: (2020)

SARS-CoV-PL(pro)-Inhibitoren als mögliche Breitspektrum-Virostatika
por: Hammerschmidt, Stefan Josef, et al.
Publicado: (2021)

Polyphenolic Compounds Isolated from Marine Algae Attenuate the Replication of SARS-CoV-2 in the Host Cell through a Multi-Target Approach of 3CL(pro) and PL(pro)
por: Nagahawatta, D. P., et al.
Publicado: (2022)

Protocol for production and purification of SARS-CoV-2 3CL(pro)
por: Mazzei, Luca, et al.
Publicado: (2023)

Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CL(pro) inhibitors
por: Nukoolkarn, Veena, et al.
Publicado: (2008)

Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Diphenyl Diselenide and SARS-CoV-2: in silico Exploration of the Mechanisms of Inhibition of Main Protease (M(pro)) and Papain-like Protease (PL(pro))
por: Omage, Folorunsho Bright, et al.
Publicado: (2023)

In Silico and In Vitro Inhibition of SARS-CoV-2 PL(pro) with Gramicidin D
por: Protić, Sara, et al.
Publicado: (2023)

Computer-aided drug design for the pain-like protease (PL(pro)) inhibitors against SARS-CoV-2
por: Gao, Hongwei, et al.
Publicado: (2023)

Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL(pro)
por: Wang, Ruyu, et al.
Publicado: (2021)

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors
por: Regnier, Thomas, et al.
Publicado: (2009)

Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro)
por: Du, Ruikun, et al.
Publicado: (2021)

Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL(pro) covalent inhibitors
por: Stille, Julia K., et al.
Publicado: (2022)

In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
por: Maulana, Saipul, et al.
Publicado: (2023)

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition
por: Ryu, Young Bae, et al.
Publicado: (2010)

Inhibition of the SARS-CoV-2 3CL(pro) main protease by plant polyphenols
por: Bahun, Miha, et al.
Publicado: (2022)

Machine learning prediction of 3CL(pro) SARS-CoV-2 docking scores
por: Bucinsky, Lukas, et al.
Publicado: (2022)

In silico studies of M(pro) and PL(pro) from SARS-CoV-2 and a new class of cephalosporin drugs containing 1,2,4-thiadiazole
por: Delgado, Cássia Pereira, et al.
Publicado: (2022)

A Bioluminescent 3CL(Pro) Activity Assay to Monitor SARS-CoV-2 Replication and Identify Inhibitors
por: Mathieu, Cyrille, et al.
Publicado: (2021)

Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL(pro) inhibitors for treating COVID-19
por: Zhang, Jian-Wei, et al.
Publicado: (2022)

Pro108Ser mutation of SARS-CoV-2 3CL(pro) reduces the enzyme activity and ameliorates the clinical severity of COVID-19
por: Abe, Kodai, et al.
Publicado: (2022)

Human Superantibodies to 3CL(pro) Inhibit Replication of SARS-CoV-2 across Variants
por: Glab-ampai, Kittirat, et al.
Publicado: (2022)

Exploration of chalcones as 3-chymotrypsin-like protease (3CL(pro)) inhibitors of SARS-CoV-2 using computational approaches
por: Lam, Thua-Phong, et al.
Publicado: (2022)

Fluorine Atoms on C(6)H(5)-Corrole Affect the Interaction with M(pro) and PL(pro) Proteases of SARS-CoV-2: Molecular Docking and 2D-QSAR Approaches
por: Chaves, Otávio Augusto, et al.
Publicado: (2022)

Virtual screening based on the structure of more than 10(5) compounds against four key proteins of SARS-CoV-2: M(Pro), S(RBD), RdRp, and PL(pro)
por: Nabati, Farzan, et al.
Publicado: (2022)

Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL(pro) and PL(pro)), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2)
por: Mouffouk, Chaima, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ct36ap4v3hhriaoh8k0u14j0f